Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elranatamab + maplirpacept
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Elranatamab + maplirpacept is a **combination therapy** under clinical investigation for the treatment of relapsed or refractory multiple myeloma. **Elranatamab** is a bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T-cells, thereby redirecting T-cells to kill myeloma cells. **Maplirpacept** (PF-07901801) is a fusion protein that acts as a decoy receptor for CD47, aiming to block the CD47-SIRPα axis that enables tumor cells to evade macrophage-mediated phagocytosis. The combination is being studied to determine its safety, optimal dosing, and preliminary efficacy in people with multiple myeloma who have relapsed or are refractory to prior treatments. Ongoing clinical trials administer elranatamab subcutaneously and maplirpacept intravenously in 4-week cycles[1][3][7].
- Other names
- elranatamab and maplirpacept
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)BCMA (B-cell maturation antigen)CD47 (Cluster of Differentiation 47)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on elranatamab + maplirpacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elranatamab + maplirpacept.